Switching from Pregabalin to Gabapentin
You should taper pregabalin gradually over a minimum of 1 week before or during the initiation of gabapentin to minimize withdrawal symptoms and adverse reactions. 1
Rationale for Tapering
Pregabalin requires gradual discontinuation to prevent withdrawal syndrome. The FDA label explicitly states that pregabalin should be tapered gradually over a minimum of 1 week rather than discontinued abruptly. 1 Following abrupt or rapid discontinuation, patients have reported withdrawal symptoms including insomnia, nausea, headache, anxiety, hyperhidrosis, and diarrhea. 1
- Withdrawal symptoms are well-documented with pregabalin. Case reports to pharmacovigilance centers have documented dependence, abuse, and withdrawal symptoms attributed to pregabalin, with more than half of affected patients requiring hospitalization for withdrawal management. 2
- The risk of withdrawal exists even in patients without prior substance abuse history. 2, 3
Transition Strategies
Two evidence-based approaches exist for transitioning between these medications:
Option 1: Gradual Cross-Taper (Preferred)
A gradual transition involving coadministration provides seamless coverage. 4 This approach involves:
- Reduce pregabalin to 50% of the current dosage 4
- Simultaneously initiate gabapentin at 50% of the target dosage 4
- Continue this overlap for 4 days 4
- Then discontinue pregabalin completely and increase gabapentin to full target dose 4
Option 2: Sequential Taper and Switch
Alternatively, complete the pregabalin taper first, then initiate gabapentin. 1
- Taper pregabalin gradually over a minimum of 1 week 1
- Once pregabalin is discontinued, begin gabapentin at low dosages (100-300 mg at bedtime or three times daily) 5
- Titrate gabapentin by 100-300 mg every 1-7 days as tolerated 5
Pharmacokinetic Considerations
Both transition methods maintain therapeutic drug exposure without significant gaps. Pharmacokinetic simulations demonstrate that pregabalin-equivalent concentrations remain stable during transition periods using either approach, with seamless coverage achieved within 1 day of the switch. 4
The medications share similar mechanisms but differ in pharmacokinetics. Both gabapentin and pregabalin bind to voltage-gated calcium channels at the α2-δ subunit and inhibit neurotransmitter release. 5 However, pregabalin has linear pharmacokinetics and higher bioavailability, while gabapentin has nonlinear pharmacokinetics due to saturable absorption. 5
Dosage Equivalency
Pregabalin is approximately 6 times more potent than gabapentin. 6 Common conversion ratios include:
- Pregabalin 150 mg/day ≈ Gabapentin 900 mg/day 4
- Pregabalin 300 mg/day ≈ Gabapentin 1800 mg/day 4
- Pregabalin 600 mg/day ≈ Gabapentin 3600 mg/day 4
Important Caveats
Monitor for side effects during transition, particularly peripheral edema. Peripheral edema occurs more frequently with pregabalin (6% vs 2% with placebo) and may persist or worsen during the transition period. 1, 6
Both medications cause dose-dependent dizziness and sedation. These adverse effects can be reduced by starting with lower dosages and titrating cautiously. 5 Dizziness occurs in 30% of pregabalin-treated patients, and somnolence in 23%. 1
Adjust dosing in renal insufficiency. Both medications require dosage reduction in patients with impaired renal function, with adjustments based on creatinine clearance. 5
Gabapentin titration requires patience. An adequate trial of gabapentin can require 2 months or more due to its nonlinear pharmacokinetics and the need for gradual dose escalation to the maximum of 3600 mg/day in three divided doses. 5